UCB's Keppra approved by European Commission for juvenile epilepsy

By Elaine Rigoli

Tampa, Fla., May 15 - UCB announced that the European Commission has approved the use of Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy, a common epilepsy syndrome that usually starts between the ages of 12 and 18.

In Europe, Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from four years of age with epilepsy and as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age.

UCB is a global biopharmaceutical company based in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.